Sarepta Therapeutics (SRPT) Tops Q1 EPS by 75c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $0.73, $0.75 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $413.5 million versus the consensus estimate of $379.15 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04
• BMO starts chip stocks coverage: Here are its preferred picks